Nimenrix is a vaccine used to protect adults, adolescents and children from the age of 6 weeks against invasive meningococcal disease caused by four groups of the bacterium Neisseria meningitidis (group A, C, W-135, and Y). Invasive disease occurs when the bacteria spread through the body causing serious infections such as meningitis (infection of the membranes that surround the brain and spine) and septicaemia (blood poisoning). The vaccine contains substances from the outer coat of the bacterium N. meningitidis.
Therapeutic Indication
### Therapeutic indication Nimenrix is indicated for active immunisation of individuals from the age of 6 weeks against invasive meningococcal diseases caused by Neisseria meningitidis group A, C, W-135, and Y.
Therapeutic Area (MeSH)
N/AATC Code
J07AH08
ATC Item
meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugated
Pharmacotherapeutic Group
Vaccines
Active Substance (Summary)
N/AINN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid | N/A | neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid |
| Neisseria meningitidis group C polysaccharide conjugated to tetanus toxoid | N/A | neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid |
| Neisseria meningitidis group W-135 polysaccharide conjugated to tetanus toxoid | N/A | neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid |
| Neisseria meningitidis group Y polysaccharide conjugated to tetanus toxoid | N/A | neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid |
EMA Name
Nimenrix
Medicine Name
Nimenrix
Aliases
N/ANo risk management plan link.
